A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Phase 1
317
about 12 years
18+
13 sites in CA, GA, IN +8
About this study
This trial is testing a new drug called linvoseltamab when combined with other cancer treatments for people whose multiple myeloma has returned after previous treatment. The goal is to see if this combination is safe and effective, and to determine the best dose of linvoseltamab in these combinations.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Bortezomib
- 2.Take Carfilzomib
- 3.Take Cemiplimab
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
bortezomib, carfilzomib, cemiplimab, monoclonal antibody, daratumumab, isatuximab, lenalidomide (Immunomodulatory drug; affects immune system and cancer cells (exact mechanism unclear)), nirogacestat
injection (Injection), infusion, oral (Oral Capsule), oral (Oral Tablet)
Primary: Incidence of adverse events of special interest (AESIs), Incidence of pre-defined safety criteria or dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period, Incidence of serious adverse events (SAEs), Incidence of treatment-emergent adverse events (TEAEs), Severity of SAEs, Severity of TEAEs
Secondary: Duration of response (DOR) by IMWG criteria, Objective response rate (ORR) as measured by International Myeloma Working Group (IMWG) criteria, Overall Survival (OS), Progression-free survival (PFS) as measured by IMWG criteria
Oncology